CRISPR Therapeutics: An Uninspiring Start For Casgevy
CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...
pharmaphorum1d
First CRISPR drug Casgevy gets swift second approval
Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. AstraZeneca and Ionis add an EU green light to ...
The Motley Fool6d
3 Magnificent Growth Stocks to Buy in March
Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...
pharmaphorum2d
After a no in sickle cell, NICE OKs Casgevy for thalassaemia
Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...
Benzinga.com7d
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Optum Rx, is the pharmacy benefit manager owned by UnitedHealth Group Inc’s UNH Also Read: HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is ...
Yahoo Finance6d
One of the top growth stocks in the industry
Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry. For pharmaceutical companies, especially those with a market cap above $50 billion, year-over ...
The Motley Fool UK6d
Could buying this gene-editing penny stock at $1 make me rich?
Along with partner Vertex Pharmaceuticals, it has won regulatory approval for Casgevy, a revolutionary treatment for SCD and beta-thalassemia. Meanwhile, Intellia is partnered with Regeneron ...